Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience
暂无分享,去创建一个
C. Creuzot-Garcher | M. Gillies | P. Gabrielle | V. Daien | D. Barthelmes | C. Chamard | E. Debourdeau | S. Allieu | V. Nguyen | R. Médard
[1] T. Wong,et al. Systemic Factors Associated with Treatment Response in Diabetic Macular Edema , 2020, Journal of ophthalmology.
[2] J. Chhablani,et al. Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity , 2020, Acta ophthalmologica.
[3] C. Creuzot-Garcher,et al. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry. , 2019, Ophthalmology.
[4] Daniel L. Chao,et al. OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema. , 2019, Ophthalmology. Retina.
[5] A. Ambrósio,et al. Evaluation of markers of outcome in real-world treatment of diabetic macular edema , 2018, Eye and Vision.
[6] N. Bressler,et al. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial , 2018, JAMA ophthalmology.
[7] A. Bruynseels,et al. Effect of glycosylated hemoglobin on response to ranibizumab therapy in diabetic macular edema: real-world outcomes in 312 patients. , 2017, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[8] J. Cunha-Vaz,et al. OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study , 2017, Retina.
[9] P. Kaiser,et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. , 2016, Ophthalmology.
[10] Rishi P. Singh,et al. The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema. , 2016, Ophthalmology.
[11] F. Wolf,et al. Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers , 2016, Clinical Diabetes.
[12] Sherri A Van Everen,et al. Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema: A Post Hoc Analysis of the RIDE/RISE Trials. , 2015, Ophthalmology.
[13] H. Hammes,et al. Risk Factors for Retinopathy and DME in Type 2 Diabetes—Results from the German/Austrian DPV Database , 2015, PloS one.
[14] P. Campochiaro,et al. Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab. , 2015, Ophthalmology.
[15] N. Bressler,et al. Prevalence of and risk factors for diabetic macular edema in the United States. , 2014, JAMA ophthalmology.
[16] P. Kaiser,et al. Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.
[17] Rishi P. Singh,et al. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. , 2014, Journal of diabetes and its complications.
[18] P. Romero-Aroca,et al. Laser Treatment for Diabetic Macular Edema in the 21st Century , 2014, Current diabetes reviews.
[19] Massimo Porta,et al. Medical management for the prevention and treatment of diabetic macular edema. , 2013, Survey of ophthalmology.
[20] N. Koo,et al. Relationship between the Morphology of Diabetic Macular Edema and Renal Dysfunction in Diabetes , 2013, Korean journal of ophthalmology : KJO.
[21] M. Mahgoub,et al. The Effect of Glycemic Control on Visual and Anatomic Outcomes in Response to Therapy for Diabetic Macular Edema , 2013, European journal of ophthalmology.
[22] Quan Dong Nguyen,et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. , 2012, Ophthalmology.
[23] B. Klein,et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy , 2012, Diabetes Care.
[24] Josef Coresh,et al. Chronic kidney disease , 2012, The Lancet.
[25] Chih-jen Wu,et al. Difference between CKD-EPI and MDRD equations in calculating glomerular filtration rate in patients with cirrhosis. , 2011, World journal of gastroenterology.
[26] S. Okudan,et al. Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema. , 2011, Journal of diabetes and its complications.
[27] Francesco Bandello,et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.
[28] Simon P. Harding,et al. Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study) , 2010, Diabetes Care.
[29] M. Elshafie,et al. Pretreatment clinical variables associated with the response to intravitreal bevacizumab (Avastin) injection in patients with persistent diabetic macular edema. , 2010, Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society.
[30] Quan Dong Nguyen,et al. Persistent diabetic macular edema is associated with elevated hemoglobin A1c. , 2005, American journal of ophthalmology.
[31] T. Bek,et al. Macular edema reflects generalized vascular hyperpermeability in type 2 diabetic patients with retinopathy. , 2002, Diabetes care.
[32] F. Akay,et al. Diabetic Macular Edema , 1969, Pakistan journal of medical sciences.
[33] R. Meirelles,et al. Use of Optical Coherence Tomography (OCT) and Indirect Ophthalmoscopy in the Diagnosis of Macular Edema in Diabetic Patients , 2004, International Ophthalmology.
[34] D. del Castillo,et al. [Prospective study of correlation between diabetic retinopathy and microalbuminuria in diabetes type 1 patients]. , 2000, Archivos de la Sociedad Espanola de Oftalmologia.
[35] R. Klein,et al. The 14-year incidence of visual loss in a diabetic population. , 1998, Ophthalmology.